MTI 2020 RESCHEDULED TO 29-30 SEPTEMBER IN LAUSANNE
London, 6 March, 2020 at 12:00PM
Campden Wealth, organiser of the MedTech Investing Europe Conference (MTI), Europe’s longest established healthcare partnering and investment event, today announces that the 30th edition of the event has been rescheduled and will take place on 29-30 September 2020 at the Hotel Royal Savoy in Lausanne Switzerland as previously scheduled.
MTI’s original 31 March – 1 April dates are changing due to growing concerns related to the spread of coronavirus (Covid-19) in Switzerland and across Europe.
“The well-being of our clients and staff is our priority. Given the evolving context, the best course of action is to postpone MTI to September,” said Campden Wealth Director of Events Peter Newton.
“This is not a decision we have taken lightly. We believe these new dates will provide the international MTI community with the opportunity to achieve their business and investment objectives. We are grateful to our clients for their support and constructive input during this challenging period, and we look forward to talking with them in the coming days about MTI in September” added Peter Newton.
We will be communicating regularly with the MTI community to provide details of MTI on 29-20 September.
Bringing Together Innovators, Leading Investors and Major Healthcare Corporations
Welcome to the 30th MedTech Investing Europe Conference, the longest-established and leading healthcare investment and partnering conference in Europe. We are delighted to once again bring together the very best game-changing technologies and leading entrepreneurs with a wide range of healthcare investors including VC’s, angel investors, leading MedTech corporations, private wealth holders, family offices and many more.
Since 2003 we have been at the centre of the rapidly evolving healthcare technology venture ecosystem and specialised in bringing together over 1000 venture-stage companies with investors ranging from VC’s to major healthcare corporations, from family offices to angel investors and many more.
We are proud to be returning to Lausanne, Switzerland, bringing the very best of the investment community to one of the world’s leading regions for technology development.
This unrivalled platform will:
The MTI events deliver the best ratio of investors to presenting companies, giving all attendees the maximum opportunity to meet, network and learn from the best in the business ensuring you meet the right investors and the right investment opportunities.
Do not miss this unique opportunity to meet with some of the most proactive entrepreneurs and investors in healthcare, learn how to fine-tune your strategy and ultimately maximise the potential for return from the sector.
The MTI conference programmes address the biggest topics in the industry today, from investment topics such as “Where is the money coming from?” and “What do family offices look for and how do they invest?” to wider challenges such as “How does healthcare economics playout in the real world?” and “How do you plan and execute a successful exit”.
The conference programmes are developed in conjunction with the MTI Investor Advisory Board – a collection of the biggest investors in the sector with assets under management of over €40bn.
Our speaking faculties represent the truly global nature of the healthcare and life science industry with panellists drawn from leading organisations from Europe, North America, the Middle East and Asia.
The core of our speaker faculty is made-up of some of the industry’s most active and ambitious investors joining on-stage discussion to give the latest insight into their investment strategy, the evolution of the sector, the most promising future opportunities and ultimately the opportunities they are looking for and to make investments in.
Leading the conference programme we are honoured to welcome back as conference chairman Dr Benoît Dubuis the Executive Director of Campus Biotech and the President of the world-renowned Inartis Foundation.
Benoît has over 30 years of international experience in Life Sciences, both in industry and in the academic world. After his engineering training, his doctorate from ETH Zurich (ETH Medal 1995) and an academic activity in Cambridge and Cranfield in England, he held various management positions in pharmaceutical companies (Chemap, Ciba-Geigy / Novartis, Lonza), before joining the École Polytechnique Fédérale de Lausanne (EPFL) where he founded the Faculty of Life Sciences.
Confirmed speakers will be updated at regular intervals as the events draws closer. If you are interested in speaking at the event please contact the event manager Peter Newton on +44(0)203 763 2800 or firstname.lastname@example.org.
Over the last 29 events we have showcased over 1000 venture-stage healthcare and life science companies to our unrivalled audience of investors. Representing all areas of healthcare and life sciences our presenting companies originate from over 37 countries and are at a range of different stages from pre-clinical to commercialisation.
For more information on how you can participate please email email@example.com.
A selection of the previously confirmed presenting companies at MTI events include:
Why attend as a delegate?
Be the first to uncover the latest investment opportunities from our unrivalled range of Presenting Companies
Meet over 40 investment opportunities all in one location over 2 days
Network with the leading investors and MedTech corporations
Learn how to adapt your investment strategy for today’s climate
Take away the tools to help your portfolio companies develop and grow to their full potential
Who are the delegates?
Every year MTI brings over 150 delegates together who are working at the cutting edge of healthcare and life science investment and partnering. Our investors represent some of the most pro-active and ambitious individuals from family offices, private wealth holders, VC’s, corporate VC’s, institutional investors, angels and managed funds to name but a few.
In order to ensure the best possible mix of investors and early-stage companies admission to all MTI events is strictly controlled and open to all qualifying companies and individuals. The organisers reserve the right to restrict admittance and delegate places.
To see examples of the range of investors MTI attracts here are just some of our previous members of the Investor Advisory Board:
Partner, Siemens Venture Capital, USA
General Partner, BioMed Partners, Switzerland
General Partner, VI Partners, Switzerland
Senior Managing Director, OrbiMed Healthcare Fund Management, Israel
Partner, Gilde Healthcare Partners, Netherlands
Managing Partner, Peppermint Venture Partners GmbH, Germany
Partner, Omega Fund Management, UK
Co-Head Venture Capital, Life Sciences Partner, Omnes Capital, France
Founding Partner, HealthCap Venture Capital, Sweden
President, Shafner Law Office, USA
How to register
Special packages and early booking price are available for delegates who book early, see the Registration Page for more information or contact:
+44 (0)203 763 2816
To enquire about sponsorship opportunities at upcoming MTI events, please contact Anthony Hackett on anthonyhackett@
Sponsors of the MTI events represent leading companies and organisations providing services to early to mid-stage life science companies, investors and major healthcare corporations. Sponsors receive unrivalled exposure and access to some of the smartest venture-stage companies, cutting-edge investors and active family offices:
Canton of Vaud
State of Vaud - Office for Economic Affairs and Innovation (SPEI)
Canton of Vaud is one of the main centers of research and innovation in Switzerland, with the largest academic and technology campus in the country and several research institutes as well as industries of international reputation, particularly in life sciences, micro-nanotechnologies, ICT and cleantech.
In a few words :
A quarter of the 100 top Swiss startups are based in Vaud including 4 of the 10 top best ones in 2018 as well as about 2,000 high-tech companies
Vaud ranked 1st in fundraising for 4 consecutive years (2014-2017) in comparison to other Swiss cantonsas Vaud-based startups have raised up to CHF 1.2 bio over the past 5 years and CHF 267.5 mio in 2018
24 scaleups are based in Vaud and created 361 new jobs in 2018
There are 7 incubators and innovation parks suitable to develop your ideas and business, pooling local infrastructure and technical skills
About CHF +32 mio financial incentives have been distributed from the State of Vaud to startups/SMEs since 2012 to support their economic development.
Through its support to the MedTech Investing Europe Conference 2020, SPEI aims to showcase our region to all the international guests for what it really is: a direct connection with world-class academic and research institutes, a dense network of internationally oriented SMEs and innovative startups, and a vibrant location offering favorable conditions to expand your business.
The Office for Economic Affairs and Innovation (SPEI) supports companies that are exclusively based in Vaud, especially those involved in the sectors of advanced technology and industry. SPEI advises entrepreneurs and puts them in contact with organizations that are appropriate to their specific needs. SPEI can also provide direct financial support.
For more information, please contact:
State of Vaud – Department of Economy, Innovation and Sport (DEIS)
Office for Economic Affairs and Innovation (SPEI)
Rue Caroline 11
CH – 1014 Lausanne
+41 21 316 58 20
BioAlps - The Lake Geneva Biotech & Medtech Cluster
BioAlps is the life science cluster of Western Switzerland. The association is an active and growing network of research institutions, academic institutions, start-up companies and large, blue chip multinationals.
The biotech and medtech sectors in BioAlps are experiencing double digit annual growth and have attracted more than CHF 500'000'000 venture capitalist investments in 2017.
The BioAlps region includes:
1118 life sciences companies
500+ research laboratories
35,000+ people employed in companies
33 research institutions, universities and university hospitals
Many science parks and incubators for start-up companies
The BioAlps region offers many assets for attracting companies and start-ups:
Strong, dynamic and economy-friendly academic research: efficient technology transfer practices
Most favourable tax rulings and conditions in Europe, particularly for new companies and international corporate structures
Incubators offering lab space, coaching and financial support
Flexibility of labour market and labour relations
Strong VC presence and public financial tools for boosting young companies’ development
Easy to attract the best scientists and managers thanks to an exceptional quality of life
Exceptional competencies in the domains of molecular and genetic biology, bioinformatics, proteomics and genomics, oncology, neurosciences, as well as in pharmaceuticals, instrumentation, diagnostics and medical devices
The BioAlps Association:
Promotes and strengthens synergies among its members in the academic and private sectors
Fully supports the transfer of technologies and competencies from academic to industrial settings
Stimulates the development of new businesses
Develops the exchange of information and resources between scientists, the financial community and government representatives
Establishes relationships with similar initiatives in life sciences at the local and national levels
Provides a communication network throughout Switzerland and internationally in which to disseminate information on its initiatives
Offers a close and friendly biotech and medtech community
For more information, please contact:
Avenue de Sécheron 15
École Polytechnique Fédérale de Lausanne, EPFL, is located on the shores of Lake Geneva in Switzerland. It has three missions: education, research and technology transfer at the highest international level. With more than 250 laboratories and research groups on campus, it is one of Europe’s most innovative and productive technology institutes.
The campus offers services and facilities to transform scientific excellence into economic competitiveness, jobs and quality of life. A start-up incubator, coaching services, study programmes in entrepreneurship and innovation programmes all serve to stimulate the links between the lab and business. The Science Park on campus is home to more than 100 enterprises and numerous investors. EPFL’s unique structure facilitates transdisciplinary research and encourages partnerships with other institutions. It emphasizes both fundamental research and engineering applications. Within the EPFL School of Engineering (STI) a wide range of laboratories are active in the field of biomedical technologies, notably in optics and imaging, medical engineering, instrumentation and biomedical signal processing.
The focus is placed on the integration of natural and artificial systems at several levels: development of new models inspired by living organisms, conception of components, tools and systems to facilitate the understanding of the functions of living systems and finally, conception and development of increasingly sophisticated medical aids. A particular emphasis is placed on biomechanics, including mechanical properties and behavior of living tissue and biomaterials, bone mechanics, biomechanics and orthopaedics, prostheses and implants and movement analysis and measurement.
It is clear that biomedical research will increasingly rely on quantitative approaches and high-end technologies. The future of life sciences lies at the crossroads of biology, hard sciences and engineering.
The EPFL School of Life Sciences (SV) was created on this premise, reflecting the thirst for biologically relevant questions amongst EPFL experts in chemistry, physics, mathematics, computer science and engineering. It comprises four institutes active in neuroscience, bioengineering, infectious diseases and cancer. Integrated approaches are pushed spanning a wide range of disciplines from functional genomics to high-tech bioengineering. In addition to the main Lausanne campus, the SV is present at the Campus Biotech in Geneva with initiatives in neuroprosthetics, the Human Brain Project and a center for Bio and Neuroengineering.
The Canton of Vaud
The canton of Vaud is one of the main centres of research and innovation in Switzerland, with the biggest university campus in the country and several public and private research institutions. The canton is also at the centre of supra-regional technical cluster, with companies located in the canton of Vaud able to benefit from close links between the research centres and industry.
Hotel Royal Savoy Lausanne
Set in the heart of Lausanne, originally built in 1909 and painstakingly restored to its pristine beauty this The Royal Savoy Hotel is now a landmark representing luxury and style complemented by an elegant yet contemporary design. Located adjacent to the majestic Lake Geneva and one hour from Geneva airport this hotel is ideal for visitors who appreciate culture, heritage and history, whilst enjoying up to date modern facilities of a first class hotel. Please book your accommodation here & send the form to Severine.Bonin@RoyalSavoy.ch.
We are working closely with Hotel Royal Savoy Lausanne to bring you discounted rates for your stay during the conference.
Please fill out the form below & send to Severine.Bonin@RoyalSavoy.ch
If you require any assistance please contact Charlotte Eliott at firstname.lastname@example.org or +44 (0) 20 763 2800.
For more information on how to secure your delegate please, please contact Blanca Morales on email@example.com or +44 (0) 20 763 2800.
There are numerous hotels close by ranging from 3* to 5*. If you wish to stay off-site, we would recommend any of the following:
|Hotel in Lausanne||Cost||Distance|
|Carlton Lausanne Boutique Hotel
4 Star Hotel
|Approx. CHF 185 p/night||1 min walk from venue|
|Agora Swiss Night by Fassbind
4 Star Hotel
|Approx. CHF 175 p /night||7 min walk from venue|
|Alpha-Palmiers Hotel by Fassbind
4 Star Hotel
|Approx. CHF 190 p /night||12 min walk from venue|
4 Star Hotel
|Approx. CHF 220 p /night||11 min walk from venue|
3 Star Hotel
|Approx. CHF 140 p /night||10 min walk from venue|
|ibis Styles Lausanne Center Mad House
3 Star Hotel
|Approx. CHF 112 p /night||17 min walk from venue|
3 Star Hotel
|Approx. CHF 135 p /night||7 min walk from venue|
Prices taken from 28th Feb 2020. Prices may change closer to time of event.
If you have deliveries, please send your materials to:
Mrs Séverine Bonin
ROYAL SAVOY HOTEL & SPA
Avenue d’Ouchy 40
1006 Lausanne – Switzerland
(Campden Wealth Event – 29 & 30 September)
Campden Wealth, 30 Cannon Street, Lower Ground Floor, London EC4M 6XH, United Kingdom